Global competition for clinical trials is intensifying, with contracting cycle times emerging as a key differentiator in Europe after regulatory harmonization under the EU Clinical Trials Regulation. France’s adoption of mandatory contract templates and centralized budgeting cut cycle times by over 40%, while Ireland saw similar improvements after standardization. Optional templates, as in Belgium and the Netherlands, show benefits only when consistently applied. Germany, long lagging due to lengthy negotiations, is moving to mandatory standard contract clauses under its National Pharmaceutical Strategy. Supported by sites and associations, this shift is expected to shorten startup times, reduce review hours, and restore competitiveness.

Join for free to read